Important Safety Information
Including Boxed Warning
KETEK is contraindicated in patients with myasthenia gravis. There have been reports of fatal and life-threatening respiratory failure in patients with myasthenia gravis associated with the use of KETEK. Continue below
Tissue Penetration
KETEK® penetrates epithelial lining fluid with levels
that exceed MICs of common pathogens in CAP- S pneumoniae and
H influenzae*.
Telithromycin concentrations in epithelial lining fluid evaluated after 800-mg once-daily
dosing for 5 days in healthy patient population.
5
*Tissue Penetration does not imply clinical effectiveness. The clinical significance of in vitro activity is unknown.